S&P 500
(0.05%) 5 250.88 points
Dow J
(0.04%) 39 776 points
Nasdaq
(-0.11%) 16 381 points
Oil
(1.59%) $82.64
Gas
(0.70%) $1.730
Gold
(1.00%) $2 234.90
Silver
(0.61%) $24.90
Platinum
(1.38%) $922.25
USD/EUR
(0.26%) $0.926
USD/NOK
(0.67%) $10.84
USD/GBP
(0.01%) $0.791
USD/RUB
(0.10%) $92.53

Realtime updates for Eupraxia Pharmaceuticals [EPRX.TO]

Exchange: TSX Industry: Biotechnology
Last Updated28 Mar 2024 @ 12:22

-0.95% $ 4.15

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 12:22):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector...

Stats
Today's Volume 13 365.00
Average Volume 52 546.00
Market Cap 113.14M
EPS $0 ( 2024-03-26 )
Next earnings date ( $-0.240 ) 2024-05-09
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -2.71
ATR14 $0.0250 (0.60%)

Eupraxia Pharmaceuticals Correlation

10 Most Positive Correlations
TCL-A.TO0.937
CFP.TO0.902
AQN.TO0.902
AW-UN.TO0.901
BLX.TO0.894
TULB.TO0.893
WTE.TO0.893
ESGF.TO0.89
NPI.TO0.89
BIP-UN.TO0.889
10 Most Negative Correlations
SUSA.TO-0.93
IAF-PI.TO-0.883
OBE.TO-0.88
MEG.TO-0.875
PEY.TO-0.87
CTZ.V-0.869
PKI.TO-0.861
RQK.TO-0.85
URB.TO-0.843
VLE.TO-0.842

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Eupraxia Pharmaceuticals Financials

Annual 2022
Revenue: $0
Gross Profit: $-193 273 (0.00 %)
EPS: $-1.210
Q3 2023
Revenue: $0
Gross Profit: $-49 906.00 (0.00 %)
EPS: $-0.250
Q2 2023
Revenue: $0
Gross Profit: $-49 186.00 (0.00 %)
EPS: $-0.360
Q1 2023
Revenue: $0
Gross Profit: $-48 617.00 (0.00 %)
EPS: $-0.230

Financial Reports:

No articles found.

Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators